Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|March 23, 2015
ICON, Carnegie Mellon Collaborate on Informed Consent Processes
Series of research projects to evaluate approaches for improving patient understanding of clinical trials
Advertisement
ICON is sponsoring a series of research projects, led by Professor Baruch Fischhoff, Ph.D., at Carnegie Mellon University, to find new ways to improve information comprehension and retention by clinical trial participants. The research tools will include multimedia solutions from ICON’s Firecrest suite of products. Fischhoff said they are using behavioral decision research and information technology to "design and evaluate approaches for ensuring that patients understand the potential risks and benefits of joining trials.”
Read the full release
Advertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Needs to Happen Beyond the Clinical Trial Modernization Act
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance
5